Get to know our clinical trials

Clinical trial to evaluate MK-6194 in adult participants with non-segmental vitiligo.

THE PRIMARY OBJECTIVE OF THE TRIAL IS TO EVALUATE THE EFFICACY OF MK-6194 IN TERMS OF PERCENTAGE CHANGE IN F-VASI (FACIAL VITILIGO AREA SCORE INDEX) SCORE BETWEEN BASELINE AND WEEK 24.

Status
In recruitment
headquarters
Madrid

Technical Summary

  • PHASE 2A, MULTICENTER, RANDOMIZED, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MK-6194 IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO
  • Code EudraCT: 2023-503502-37
  • Protocol number: MK-6194-007
  • Promoter: Merck Sharp & Dohme, S.A.
  • Molecule/Drug: MK-6194

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.